Pay-for-delay ban now hinges on Senate
Wednesday, 7 July 2010
Ron Knox
The US House of Representatives has approved measures that would limit the circumstances when branded drug companies can enter into settlement agreements with potential generic challengers.
PREMIUM Subscription required to view this article
This content can only be accessed by PREMIUM GCR subscribers.
A premium subscription includes 10 issues of the journal, 2 signature surveys - The GCR100 and Rating Enforcement, 10 GCR special reports and full access to current and archived print & online content.
If you are a GCR subscriber, please login to access this content:
Comments
You must Subscribe or Log In to make comments.
Comment Terms & Conditions
Back to top